SCN2A and epilepsy: In some cases, the ASM may be targeted to the specific underlying disease mechanisms (e.g. the use of sodium channel-blocking ASMs for the treatment of seizures in individuals with SCN2A-related epilepsies due to gain-of-function variants [119]).